Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Status:
Recruiting
Trial end date:
2030-10-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is
safe and effective in treating your condition of metastatic (spread to other parts of your
body) uveal melanoma. This research study will test the study drugs to see if the combination
of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Genzyme, a Sanofi Company Regeneron Pharmaceuticals